文献速递膀胱癌与上尿路尿路上皮癌

顺铂不耐受转移性尿路上皮癌中PD-1/L1抑制剂与卡铂化疗的序贯策略

Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
PubMed 文献 · J Urol · 2020-09-16

该多中心回顾性研究纳入146例顺铂不耐受的转移性尿路上皮癌患者,比较一线PD-1/L1抑制剂后二线卡铂化疗(43例)与相反顺序(103例)的疗效。两组总生存无显著差异(HR 1.05,p=0.85),仅转移部位与总生存显著相关(p=0.002)。

要点

  • 卡铂化疗的客观缓解率高于PD-1/L1抑制剂(一线45.6% vs 9.3%,二线44.2% vs 21.3%)
  • 治疗序贯与总生存无关(HR 1.05,p=0.85)
  • 转移部位是唯一与总生存显著相关的因素(p=0.002)

核心结论

  • 在生物标志物未选择的顺铂不耐受转移性尿路上皮癌患者中,PD-1/L1抑制剂后卡铂化疗与相反顺序的总生存相当。

研究设计与样本

  • 多中心回顾性分析,纳入146例顺铂不耐受的转移性尿路上皮癌患者,一线PD-1/L1抑制剂后二线卡铂化疗组43例,相反顺序组103例。

主要发现

  • 总体队列中位年龄72岁,76%为男性,18%有肝转移。
  • 卡铂化疗的客观缓解率在一线为45.6%、二线为44.2%,PD-1/L1抑制剂在一线为9.3%、二线为21.3%。
  • 多因素分析显示治疗顺序与总生存无关(HR 1.05,p=0.85)。
  • 转移部位是唯一与总生存显著相关的因素(p=0.002)。

临床怎么用

  • 对于顺铂不耐受的转移性尿路上皮癌患者,一线选择PD-1/L1抑制剂或卡铂化疗均可,序贯顺序不影响总生存。

局限性

  • 回顾性研究设计,样本量有限,生物标志物未选择,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current first line treatment options in patients with metastatic urothelial carcinoma unfit to receive cisplatin containing chemotherapy include PD-1/L1 inhibitors and carboplatin containing chemotherapy. However, the optimal sequencing of these therapies remains unclear. MATERIALS AND METHODS: We conducted a multicenter retrospective analysis. Consecutive cisplatin ineligible patients with metastatic urothelial carcinoma treated with first line carboplatin containing chemotherapy followed sequentially by second line PD-1/L1 inhibitor, or the reverse order, were included. Patient demographics, objective response, time to treatment failure for first line and second line therapy, interval between end of first line and initiation of second line treatment (Interval1L-2L) and overall survival were collected. Multivariate analysis was conducted to examine the association of sequencing on overall survival. RESULTS: In this multicenter retrospective study we identified 146 cisplatin ineligible patients with metastatic urothelial carcinoma treated with first line PD-1/L1 inhibitor therapy followed by second line carboplatin containing chemotherapy (group 1, 43) or the reverse sequence (group 2, 103). In the overall cohort median age was 72, 76% were men and 18% had liver metastasis. In both groups objective response rates were higher with carboplatin containing chemotherapy (45.6% first line, 44.2% second line) compared to PD-1/L1 inhibitors (9.3% first line, 21.3% second line). On multivariate analysis treatment sequence was not associated with overall survival (HR 1.05, p=0.85). Site of metastasis was the only factor significantly associated with overall survival (p=0.002). CONCLUSIONS: In this biomarker unselected cohort of cisplatin ineligible patients with metastatic urothelial carcinoma, PD-1/L1 inhibitor followed by carboplatin containing chemotherapy and the reverse sequence had comparable overall survival.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Wei XX, Werner L, Teo MY, et al. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. J Urol. 2020. PMID: 32935617. doi:10.1097/JU.0000000000001371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。